The promising trial results may be a breakthrough for cisplatin-ineligible patients with muscle-invasive bladder cancer.

The KEYNOTE-905 study is ongoing and will evaluate other endpoints including EFS, OS, and pCR rate for neoadjuvant and adjuvant pembrolizumab vs surgery alone.

New trial results reveal enfortumab vedotin and pembrolizumab significantly improve survival for muscle-invasive bladder ...

Cylembio is a therapeutic cancer vaccine candidate that targets cells and immune-suppressive cells in the tumor microenvironment through activation and expansion of T cells against IDO1 and/or PD-L1 ...

New trial results reveal that pembrolizumab and enfortumab vedotin significantly enhance survival rates for muscle-invasive ...

Biontech Se Sponsored Adr (($BNTX)) announced an update on their ongoing clinical study. BioNTech SE is conducting a ...

A phase 3 study shows Cylembio combined with pembrolizumab improves progression-free survival in advanced melanoma, ...

Sustained benefits seen in overall survival, progression-free survival, objective response rate with combo vs sunitinib.

“These results from EV-303 represent a breakthrough for cisplatin-ineligible patients with muscle-invasive bladder cancer, demonstrating the potential of PADCEV in combination with KEYTRUDA when used ...

IO Biotech reported its phase 3 trial readout on melanoma immunotherapy. Check out my updated investment thesis on IOBT stock ...

Pembrolizumab, an anti–programmed death 1 (PD-1) monoclonal antibody, is a cornerstone of first-line standard care for recurrent and metastatic HNSCC. 1,2,7 The addition of pembrolizumab to ...

Background: Recent data from the KEYNOTE-590 study demonstrated the superiority of pembrolizumab plus chemotherapy compared with chemotherapy as first-line treatment for unresectable locally advanced ...